Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])
Carvelli et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005683
https://c19early.org/carvelli.html